FEC 100 for early breast cancer: 4 cycles may be sufficient

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • In patients with high-risk, early-stage breast cancer, administration of 4 cycles of adjuvant chemotherapy (FEC 100: 5-fluorouracil [Adrucil]/epirubicin [Ellence]/cyclophosphamide [Cytoxan]) vs 6 cycles had no difference in DFS and OS 6 y later.
Why this matters
  • This is 1 of the first studies to assess optimal duration of adjuvant chemotherapy for high-risk node-negative (N−) early-stage breast cancer.
Study design
  • 1515 women with high-risk, node-negative early breast cancer were randomly assigned to arm A (6 cycles of FEC 100) or arm B (4 cycles of FEC 100) after breast surgery.
  • Inclusion criteria required tumor size T≥1 cm and at...